Drug-resistant fungus infects thousands across the U.S

In 2026, the United States has seen a significant rise in cases of Candida auris, a drug-resistant fungus, with 3,437 clinical cases reported across 27 states as of July 25. California has the highest number of cases, accounting for 873, which is approximately one-quarter of the total cases in the country. Other states with notable case numbers include Texas, Tennessee, Ohio, and Georgia, among others. The CDC has indicated that this fungus primarily affects patients in healthcare settings, particularly those with severe underlying medical conditions, making them more susceptible to infections.

Candida auris is a type of yeast that can lead to serious infections, especially in hospitals and nursing homes. It spreads through contaminated surfaces and equipment, as well as through individuals who carry the fungus without showing symptoms. The health implications of C. auris can range from asymptomatic colonization to severe invasive infections, including bloodstream infections, which can be fatal. The mortality rates for invasive infections can be alarmingly high, ranging from 30% to 72%, although many affected patients are already critically ill.

The resistance of C. auris to multiple antifungal drugs complicates treatment options. Over 90% of U.S. samples are resistant to fluconazole, a commonly used antifungal medication. Echinocandins are currently the main treatment option, but some strains of the fungus have shown resistance to all three main classes of antifungals. This situation highlights a broader issue of emerging antibiotic resistance, which poses a significant challenge to public health in the U.S. and globally.

As the number of cases continues to rise, health officials are emphasizing the importance of infection control measures in healthcare settings to prevent further spread. The CDC is actively monitoring the situation and providing guidance to healthcare facilities on how to manage and contain outbreaks of this dangerous fungus. The ongoing emergence of drug-resistant organisms like Candida auris underscores the urgent need for continued research and development of effective treatments and preventive strategies.